Full Range Available Now! Supporting Paclitaxel Impurity Research

Paclitaxel is a diterpenoid compound isolated and purified from plants of the Taxaceae family. It is a classic anticancer drug widely used globally, known for its ideal efficacy and low toxicity.

In December 1992, Paclitaxel received FDA approval in the United States, becoming a vital weapon in cancer treatment. As a highly effective and low-toxicity natural anticancer agent, it primarily combats cancer cells through a unique mechanism. Paclitaxel promotes the polymerization of tubulin and inhibits its depolymerization, thereby stabilizing the microtubule system. This interferes with the normal division process of cancer cells, ultimately inducing cell death.

With the increasing prevalence of cancer and ongoing research into novel Paclitaxel formulations, the global Paclitaxel market is showing steady growth. From initial natural extraction to semi-synthetic production, and now to the latest biosynthesis research, cutting-edge studies are expanding Paclitaxel‘s potential across multiple dimensions. Innovative dosage forms are gradually becoming research hotspots, as these new technologies not only enhance therapeutic efficacy but also improve the patient treatment experience.

However, due to Paclitaxel‘s complex chemical structure, research on impurities introduced during the development and production of related drugs faces significant challenges.

SZEB advantageously supplies a full range of Paclitaxel impurity reference standards available for immediate delivery. This includes the Paclitaxel EP Impurity Series, Paclitaxel photodegradation products, Paclitaxel side chain impurities, and more. These products are suitable for impurity identification and analytical method development for Paclitaxel, supporting pharmaceutical companies in their R&D applications and ensuring drug quality.